Cabazitaxel

Drug Profile

Cabazitaxel

Alternative Names: 116 258; Jevtana; RPR 116258; RPR 116258A; Taxoid-116258; TXD 258; XRP6258

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer AIO Studien gGmbH; Bristol Haematology and Oncology Centre; European Organisation for Research and Treatment of Cancer; German Breast Group; Sanofi; SCRI Development Innovations; Sidney Kimmel Cancer Center; University Hospitals Bristol NHS Foundation Trust
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Brain metastases; Breast cancer; Germ cell and embryonal neoplasms; Liposarcoma; Penile cancer; Small cell lung cancer; Urogenital cancer
  • Phase I/II Solid tumours
  • Phase I Gastric cancer; Head and neck cancer

Most Recent Events

  • 02 May 2017 Sanofi terminates a phase II trial due to lack of significant signal of efficacy in Brain metastases (Combination therapy) in USA (IV) (NCT01934894)
  • 27 Apr 2017 European Organisation for Research and Treatment of Cancer and Sanofi resumes recruitment in a phase II trial for Liposarcoma (Metastatic disease, Inoperable/Unresectable) in United Kingdom, Italy, France and Belgium (NCT01913652)
  • 30 Mar 2017 Sanofi completes a phase II trial in Urogenital cancer (Second-line therapy or greater) in USA (IV) (NCT01437488)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top